The anti-dyslipidemia effects may be involved in the downregulation of adipogenic and lipogenic genes (C/EBP-α/-β, SREBP1, PPARγ, and FAS) and the upregulation of genes exerting transcriptional roles in lipolysis and β-oxidation (PPARα and UCP2) [42]. This evidence concerns the gene PPARG and metabolic syndrome.